2158-02-3 | Morpholine-4-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
100mg	95%	in stock	$21.00	$15.00
250mg	95%	in stock	$35.00	$25.00
1g	95%	in stock	$43.00	$31.00
5g	95%	in stock	$180.00	$126.00
25g	95%	in stock	$713.00	$499.00
100g	95%	in stock	$1,957.00	$1,370.00

Description

• Catalog Number: AF53373
• Chemical Name: Morpholine-4-carboxamide
• CAS Number: 2158-02-3
• Molecular Formula: C5H10N2O2
• Molecular Weight: 130.1451
• MDL Number: MFCD00085717
• SMILES: NC(=O)N1CCOCC1
• NSC Number: 10542

Computed Properties

• Complexity: 110
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 9
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• XLogP3: -1.2

Literature

• Synthesis, antitumor, antitrypanosomal and antileishmanial activities of benzo[4,5]canthin-6-ones bearing the N'-(Substituted benzylidene)-carbohydrazide and N-Alkylcarboxamide groups at C-2.

  Chemical & pharmaceutical bulletin 20120101

• Asymmetric synthesis of (+)-galbelgin, (-)-kadangustin J, (-)-cyclogalgravin and (-)-pycnanthulignenes A and B, three structurally distinct lignan classes, using a common chiral precursor.

  The Journal of organic chemistry 20110819

• New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis.

  PloS one 20110101

• Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs.

  PloS one 20110101

• The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents.

  International journal of endocrinology 20110101

• Structural insights into substrate specificity in variants of N-acetylneuraminic Acid lyase produced by directed evolution.

  Journal of molecular biology 20101119

• In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100911

• BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080401

• Lewis base activation of Lewis acids: catalytic, enantioselective vinylogous aldol addition reactions.

  The Journal of organic chemistry 20070720

• Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors.

  Calcified tissue international 20070101

• Lewis base activation of Lewis acids. Vinylogous aldol addition reactions of conjugated N,O-silyl ketene acetals to aldehydes.

  Journal of the American Chemical Society 20060201

• Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives.

  Journal of medicinal chemistry 20040408

• Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.

  British journal of pharmacology 20030601

• BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates.

  FEBS letters 20030211

• Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.

  Journal of medicinal chemistry 20010802

• Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids.

  Journal of cellular biochemistry 20010101